Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: A randomized controlled trial

Journal of Hepatology

Volumn 41, Issue 3, 2004, Pages 474-481

  Bruno, Savino ^a   Cammà, Calogero ^b,c   Di Marco, Vito ^b   Rumi, Mariagrazia ^d   Vinci, Maria ^e   Camozzi, Mario ^e   Rebucci, Chiara ^f   Di Bona, Danilo ^b   Colombo, Massimo ^d   Craxì, Antonio ^b   Mondelli, Mario U ^f   Pinzello, Giovanbattista ^e  

^a SAN PAOLO HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Combination therapy; Fibrosis; Multicenter trial

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSIS; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; LIVER BIOPSY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPSYCHIATRY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG TOLERANCE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; SAFETY;

EID: 4344578833     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.05.012     Document Type: Article

References (18)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237 S244
4. D. Schwartz, and J. Lellouch Explanatory and pragmatic attitudes in therapeutical trials J Chronic Dis 20 1967 637 648
5. R. de Franchis Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension J Hepatol 33 2000 846 852
6. EASL International Consensus Conference on Hepatitis C Paris 26-27 February 1999 Consensus Statement J Hepatol 31 1999 S3 S8
7. K.G. Ishak Chronic hepatitis: morphology and nomenclature Mod Pathol 7 1994 690 713
8. D. Moher, K.F. Schulz, and D.G. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials Ann Intern Med 134 2001 657 662
9. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
10. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
11. SAS Technical Report, SAS/STAS software: changes and enhancement, release 6.07. Cary, NC:SAS Institute Inc; 1992.
12. F. Davidoff, C.D. DeAngelis, J.M. Drazen, J. Hoey, L. Hojgaard, and R. Horton Sponsorship, authorship, and accountability Ann Intern Med 135 2001 463 466
13. S. Zeuzem, E. Herrmann, J.H. Lee, J. Fricke, A.U. Neumann, and M. Modi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a Gastroenterology 120 2001 1438 1447
14. S.J Hadziyannis, H. Sette Jr, and T.R. Morgan Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
15. A.M. Di Bisceglie, and J.H. Hoofnagle Optimal therapy of hepatitis C Hepatology 36 2002 S121 S127
16. M. Buti, F. Sanchez-Avila, Y. Lurie, C. Stalgis, A. Valdes, and M. Martell Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin Hepatology 35 2002 930 936
17. J. Cuzick, R. Edwards, and N. Segnan Adjusting for non-compliance and contamination in randomized clinical trials Stat Med 16 1997 1017 1029
18. E.J. Goetghebeur, and S.H. Shapiro Analysing non-compliance in clinical trials: ethical imperative or mission impossible? Stat Med 15 1996 2813 2826